May inhibit transmission of reflexes at spinal level, possibly by action (hyperpolarization) at primary afferent fiber terminals, resulting in relief of muscle spasticity; has CNS depressant properties.
Treatment of spasms from rheumatic disorders, stroke, cerebral palsy and Parkinson disease; use of intrathecal form via IV, IM, subcutaneous, or epidural routes.
Use Cautiously in:
CV: Hypotension (2%); hypertension (1%); chest pain, palpitations.
CNS: Somnolence (21%); headache (11%); convulsions (10%); dizziness (8%); paresthesia (7%); asthenia, coma, confusion, depression, insomnia (2%); abnormal thinking, agitation, anxiety, dysautonomia, hallucinations, tremor (1%); drowsiness, euphoria, lethargy, numbness, seizures, weakness in lower extremities.
DERM: Pruritus (4%); urticaria (1%); rash.
EENT: Amblyopia (2%); diplopia (1%); blurred vision, nasal congestion, taste disorder, tinnitus.
GI: Nausea and vomiting (11%); vomiting (9%); nausea (7%); constipation (5%); dry mouth, increased salivation (3%); diarrhea (2%); anorexia (1%); abdominal pain.
GU: Urinary retention (8%); impotence, urinary incontinence, urination impaired (2%); urinary frequency (1%); dysuria, enuresis.
RESP: Hypoventilation (4%); pneumonia (2%); dyspnea (1%).
OTHER: Hypotonia (35%); hypertonia (6%); accidental injury, pain, speech disorder (4%); peripheral edema (3%); back pain (2%); chills, fever (1%); ankle edema, excessive perspiration, muscle pain, slurred speech, weight gain.
CNS depressants (eg, alcohol)
May cause increased sedative effects.
May cause hypotension and dyspnea.
Therapeutic Classification: antispasticity agents, skeletal muscle relaxants (centrally acting)
Absorption: Well absorbed after oral administration.
Distribution: Widely distributed; crosses the placenta.
Metabolism/Excretion: 70–80% eliminated unchanged by the kidneys.
Half-life: 2.5–4 hr.
Copyright ©Nims Drugs2015. All rights reserved.
Powered by : web creation Nepal